| Similar Articles |
 |
Wired July 2004 Chris Mooney |
Cocktail Hour Get ready for high-speed pharmbots that mix and match drugs and doses by the millions.  |
Bio-IT World February 10, 2003 Malorye Branca |
Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.  |
The Motley Fool November 30, 2010 Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.  |
BusinessWeek May 21, 2007 Gene G. Marcial |
CombinatoRx Has A Rich Pipeline Even though CombinatoRx is tiny, the institutional big guns own stock.  |
Bio-IT World April 15, 2003 Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.  |
Bio-IT World February 11, 2005 Mark D. Uehling |
New Software for HTS Discovery tools: a Columbia University laboratory information system named SLIMS (Small Laboratory Information System) picks old drug for new disease, spinal muscular atrophy.  |
Bio-IT World December 15, 2003 Malorye A. Branca |
Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful.  |
Pharmaceutical Executive September 1, 2013 Stan Bernard |
The Drug Combination Competition Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share.  |
CIO October 15, 2001 Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...  |
Bio-IT World September 9, 2002 John P. Helfrich |
Data Management in High-Throughput Screening The high-throughput drug discovery field requires an optimal IT platform.  |
Bio-IT World June 17, 2004 John Garvey |
Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.  |
The Motley Fool October 26, 2010 Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer."  |
The Motley Fool October 27, 2010 Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.  |
Bio-IT World November 2005 |
News Blast Invitrogen has acquired Quantum Dot Corp and BioPixels... CombinatoRX and Angiotech Pharmaceuticals strike an agreement... Caliper Life Sciences to close NovaScreen BioSciences... Rosetta Biosoftware and Agendia working together...  |